Keywords: bayer/onyx, initiate, ph, iii, nexavar, trial, liver

Bayer/Onyx initiate Ph III Nexavar trial in liver cancer

Article | 01 September 2008

Print This

Germany's Bayer HealthCare and the USA's Onyx Pharmaceuticals have initiated a new Phase III trial of Nexavar (sorafenib) in liver ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in